Pardieck, Iris N. http://orcid.org/0000-0003-1642-1857
van der Sluis, Tetje C. http://orcid.org/0000-0003-1804-1647
van der Gracht, Esmé T. I. http://orcid.org/0000-0002-8329-7916
Veerkamp, Dominique M. B. http://orcid.org/0000-0003-2761-1015
Behr, Felix M. http://orcid.org/0000-0002-1158-5011
van Duikeren, Suzanne http://orcid.org/0000-0001-7391-5832
Beyrend, Guillaume http://orcid.org/0000-0001-9044-3486
Rip, Jasper http://orcid.org/0000-0001-5780-9271
Nadafi, Reza
Beyranvand Nejad, Elham http://orcid.org/0000-0002-9801-1351
Mülling, Nils http://orcid.org/0000-0002-3534-233X
Brasem, Dena J.
Camps, Marcel G. M.
Myeni, Sebenzile K. http://orcid.org/0000-0002-5813-0065
Bredenbeek, Peter J.
Kikkert, Marjolein http://orcid.org/0000-0002-5779-7386
Kim, Yeonsu
Cicin-Sain, Luka http://orcid.org/0000-0003-3978-778X
Abdelaal, Tamim http://orcid.org/0000-0003-2719-5736
van Gisbergen, Klaas P. J. M. http://orcid.org/0000-0003-3623-7555
Franken, Kees L. M. C.
Drijfhout, Jan Wouter http://orcid.org/0000-0003-4808-5296
Melief, Cornelis J. M.
Zondag, Gerben C. M.
Ossendorp, Ferry
Arens, Ramon http://orcid.org/0000-0001-5058-4110
Funding for this research was provided by:
The Gisela Thier Fellowship
LUMC (BWplus) and the graduate program of the Dutch Research Council
Helmholtz Association's Initiative and Networking Fund (the Project “Virological and immunological determinants of COVID-19 pathogenesis – lessons to get prepared for future pandemics
Health Holland (LSH-TKI project LSHM20036) Dutch Research Council
Article History
Received: 17 December 2021
Accepted: 30 June 2022
First Online: 8 July 2022
Competing interests
: C.J.M.M. is Chief Scientific Officer of ISA Pharmaceuticals, a biotech company developing novel therapeutic vaccines against cancer and virus infections. G.C.M.Z. is employee of Immunetune BV, a company developing DNA vaccines against cancer and coronaviruses. All other authors declare no competing interests exist.